Publications by authors named "Luc van Rompaey"

Claim this Profile
V
Valence and avidity determine the agonistic activity of anti-TNFR2 nanobody fusion proteins.
Mohamed A Anany, Daniela Siegmund, Olena Zaitseva, Isabell Lang, Bayan Mouhandes, Luc van Rompaey

Cell Chem Biol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generic design principles for antibody-based tumour necrosis factor (TNF) receptor 2 (TNFR2) agonists with FcγR-independent agonism.
Mohamed A Anany, Stefanie Haack, Isabell Lang, Julia Dahlhoff, Juan Gamboa Vargas, Luc van Rompaey

Theranostics· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Nicolas Leupin, Pier Luigi Zinzani, Franck Morschhauser, Stéphane Dalle, Marie Maerevoet, Luc van Rompaey

Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The NHance Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.
Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Philippe Barthélémy, Christophe Borg, Luc Van Rompaey

Biomedicines· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.
Carsten Riether, Thomas Pabst, Sabine Höpner, Ulrike Bacher, Magdalena Hinterbrandner, Luc van Rompaey

Nat Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method.
Tal Flieswasser, Valérie Camara-Clayette, Alina Danu, Jacques Bosq, Vincent Ribrag, Luc Van Rompaey

Cancers (Basel)· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.
Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Fritz Offner, Dominique Bron, Luc Van Rompaey

Clin Cancer Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.
Christel J Menet, Stephen R Fletcher, Guy Van Lommen, Raphael Geney, Javier Blanc, Luc Van Rompaey

J Med Chem· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.
Luc Van Rompaey, René Galien, Ellen M van der Aar, Philippe Clement-Lacroix, Luc Nelles

J Immunol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in the discovery of selective JAK inhibitors.
Christel J Menet, Luc Van Rompaey, Raphaël Geney

Prog Med Chem· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peroxisome proliferator-activated receptor gamma enhances the activity of an insulin degrading enzyme-like metalloprotease for amyloid-beta clearance.
Ira Espuny-Camacho, Diana Dominguez, Pascal Merchiers, Luc Van Rompaey, Dennis Selkoe

J Alzheimers Dis· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arrayed adenoviral expression libraries for functional screening.
Frits Michiels, Helmuth van Es, Luc van Rompaey, Pascal Merchiers, Bart Francken

Nat Biotechnol· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis